Neuvivo requests FDA approval of ALS treatment NP001
Oct 9, 2024 · Neuvivo has filed an application with the U.S. Food and Drug Administration (FDA) requesting the approval of its investigational therapy NP001 (sodium chlorite) to treat amyotrophic lateral sclerosis (ALS). The new drug application comes on the heels of combined data from Phase 2a (NCT01281631) and Phase 2b (NCT02794857) clinical trials, in ...
Scientists validate blood test that may speed up diagnosis of ALS
Sep 25, 2024 · Biomarker test could be widely available within 2 years, scientists say. Blood levels of eight small molecules called microRNAs can accurately distinguish people with amyotrophic lateral sclerosis (ALS) from healthy people or those with other neurodegenerative diseases, a study shows. Its developers believe this so-called “ALS fingerprint ...
MDA 2024: Planned Phase 3b trial aims to show NurOwn's efficacy
Mar 6, 2024 · A pivotal, Phase 3b clinical trial is planned to test the cell-based therapy NurOwn (debamestrocel) in people with amyotrophic lateral sclerosis (ALS), the treatment’s developer, Brainstorm Cell Therapeutics, announced.. The study’s design, based on positive findings from a previous Phase 3 trial in patients with less advanced disease, is under U.S. Food and Drug Administration (FDA) review.
ALS News Today Home | ALS News Today
Nov 5, 2024 · Ontario commits CA$13 million to address ALS community needs. The government of Ontario has committed CA$13 million (around $9.36 million) over three years to provide critical and comprehensive care to people with amyotrophic lateral sclerosis (ALS) who live in the Canadian province. The funding, which was announced in Ontario’s 2024 Fall ...
Clene granted in-person FDA meeting on CNM-Au8 for ALS
Sep 24, 2024 · Clene has been granted an in-person meeting with the U.S. Food and Drug Administration (FDA) — to be held before the end of November, according to the company — to discuss a potential accelerated approval of CNM-Au8 as a treatment for amyotrophic lateral sclerosis (ALS). Clene.
A new ALS app called Roon shares wisdom from experts and …
Sep 27, 2024 · More than 100 world-class ALS experts from top medical institutions and others in the community have generously recorded the video answers they’ve always wished patients could have access to outside of the clinic. Their answers appear in easy-to-navigate guides covering symptoms, diagnosis, treatments, clinical trials, science and research ...
News Archives - ALS News Today
Ontario commits CA$13 million to address ALS community needs. The government of Ontario has committed CA$13 million (around $9.36 million) over three years to provide critical and comprehensive care to people with amyotrophic lateral sclerosis (ALS) who live in the Canadian province. The funding, which was announced in Ontario’s 2024 Fall ...
PrimeC, potential ALS treatment, given US patent for its formulation
Oct 2, 2024 · Neurosense Therapeutics announced that it has received a U.S. patent covering the formulation of PrimeC, its lead investigational therapy for people with amyotrophic lateral sclerosis (ALS) that combines two approved medications in a fixed dose. The patent, “Compositions comprising Ciprofloxacin and Celecoxib,” was issued by the United ...
Man controls Alexa with thoughts via brain-computer interface
Sep 19, 2024 · The 64-year-old man, identified in a Synchron press release as Mark, lost the function of his upper limbs due to ALS. He was implanted with the BCI as part of a clinical trial. While control of Alexa devices typically involves the ability to tap a screen or speak, Mark is able to use his thoughts to directly control his smart home via the Tap to Alexa feature on an Amazon Fire tablet, Synchron ...
Short course of treatment with RNS60 extends survival in ALS
Sep 23, 2024 · A short course of treatment with Revalesio ‘s RNS60 as an add-on to standard amyotrophic lateral sclerosis (ALS) therapies extended the median survival of people with the progressive disease by about six months compared with a placebo. That’s according to up to six years of data from an investigator-sponsored Phase 2 clinical trial ...